PALI PALISADE BIO, INC.

NEUTRAL Impact: 4/10 EFFECT
Horizon weeks Filed May 22, 2026 Processed 22d 1h ago SEC 9999999995-26-001731
IPO/offering going effective
Latest settled — T+5d
PALI ▲ +6.67% at T+5d
NEUTRAL call ✓ call won +6.67% · α vs SPY +5.01% · entry $1.95 → $2.08
Next anchor: T+20d in 10d
Currently $1.71 · -12.31% from $1.95 entry
Entry anchored
May 22, 2026
via day open
T+1d
+2.05%
call +2.05% · α +1.47%
$1.99
settled 18d ago
T+5d
+6.67%
call +6.67% · α +5.01%
$2.08
settled 12d ago
T+20d
call — · α —
in 10d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Palisade Bio's $300M universal shelf registration (File No. 333-295815) became effective on May 21, 2026, enabling the company to offer and sell securities at any time. The company had $132.6M in cash as of March 31, 2026, and management has stated existing cash funds operations through key Phase 2 readouts in 2H 2027 and early 2028, suggesting this is an opportunistic shelf filing rather than an imminent dilutive event.

Actionable Insight

Monitor for any subsequent prospectus supplement or takedown notice, which would signal an actual offering. The shelf becoming effective is a procedural step; the stock is unlikely to react until a specific offering is announced.

Key Facts

  • Shelf registration (File No. 333-295815) declared effective on May 21, 2026.
  • Company reported $132.6M in cash as of March 31, 2026.
  • Management states existing cash funds operations through Phase 2 readouts in 2H 2027 and early 2028.
  • Shelf provides maximum flexibility for future capital raises but no immediate offering announced.

Financial Impact

Up to $300M in potential future offerings, but no immediate dilution as no takedown has occurred.

dilutioncash

Risk Factors

  • Potential future dilution if the company conducts an offering under the shelf.
  • Market may perceive shelf effectiveness as overhang, especially for a pre-revenue biotech.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001731
Document: 9999999995-26-001731-index.html9999999995-26-001731
Document: 9999999995-26-001731.txt9999999995-26-001731
5 reports for PALI
Performance horizon
Filters
Rows
Reports for PALI — sortable, filterable
Type Now
Jun 11, 2026
1d ago
8-K
NEUTRAL ★ 4/10
$1.79 awaiting T+5awaiting T+5$1.71 (−4.20%)
May 22, 2026
22d ago
EFFECT
NEUTRAL ★ 4/10
$1.95 $2.08▲ +6.67%▲ +5.01%$1.71 (−12.31%)
May 12, 2026
4w ago
S-3
NEUTRAL ★ 5/10
$1.87 $1.81▼ −3.21%▼ −2.05%$1.71 (−8.56%)
Apr 29, 2026
6w ago
DEFA14A
NEUTRAL ★ 2/10
$2.00 $1.99▼ −0.50%▼ −2.23%$1.71 (−14.50%)
Apr 2, 2026
10w ago
8-K
NEUTRAL ★ 5/10
$1.89 $1.82▼ −3.70%▼ −7.32%$1.71 (−9.52%)
Showing 5 of 5

US Market Status

Market Closed — Opens Mon (49h 42m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access